Literature DB >> 19935644

Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases.

Eyas M Hattab1, Sarah E Martin, Sohaib M Al-Khatib, William J Kupsky, Gail H Vance, Ryan A Stohler, Magdalena Czader, Mousa A Al-Abbadi.   

Abstract

Primary central nervous system lymphomas are rare neoplasms characterized by a dismal prognosis relative to other extranodal lymphomas. Approximately 98% of primary central nervous system lymphomas are of B-cell origin, and most belong to the diffuse large B-cell type. Recently, diffuse large B-cell lymphomas have been subcategorized into germinal center and nongerminal center types based on gene expression profiles and immunohistochemical expression of CD10, Bcl-6, and MUM1. Studies have shown that the overall survival rate of the germinal center group is better than that of the nongerminal center lymphomas. In this study, 31 cases of primary central nervous system lymphomas of the diffuse large B-cell type were retrieved, reviewed, and immunostained for CD10, Bcl-6, MUM1, and Ki-67. Subclassification was carried out as described earlier, where CD10 and/or Bcl-6 positivity and negativity for MUM1 were considered characteristic of germinal center subtype and the opposite expression of nongerminal center subtype. Furthermore, the proliferative activity was semiquantitatively assessed using percent positive cells staining with Ki-67. Of the 31 cases examined, 26 (84%) were found to belong to the nongerminal center type. The Ki-67 index in these 26 cases ranged from 30 to 90% (mean, 69%). Five cases were categorized as the germinal center subtype. They had an Ki-67 index between 70 and 90% (mean, 78%). Interestingly, none of our patients were known to be HIV positive. One patient had a 10-year history of orthotopic liver transplant. We also performed fluorescence in situ hybridization analysis on formalin-fixed material and found that 38% of the cases where tissue was available had abnormalities of MYC/IGH and/or IGH/BCL2. We conclude that most primary central nervous system diffuse large B-cell lymphomas are of the nongerminal center origin. Regardless of the germinal center status, all cases showed a high proliferative rate. A statistically significant difference in the overall survival between the two groups was not seen.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19935644     DOI: 10.1038/modpathol.2009.164

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  21 in total

1.  Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification.

Authors:  Indraneel Bhattacharyya; Hardeep K Chehal; Donald M Cohen; Samer Z Al-Quran
Journal:  Head Neck Pathol       Date:  2010-06-09

2.  Clinicopathological study of gene rearrangement and microRNA expression of primary central nervous system diffuse large B-cell lymphomas.

Authors:  Jinfeng Zheng; Jiagang Xu; Shufang Ma; Xiyan Sun; Ming Geng; Lin Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-09-15

3.  BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma.

Authors:  Keishi Makino; Hideo Nakamura; Naoki Shinojima; Jun-Ichiro Kuroda; Shigetoshi Yano; Yoshiki Mikami; Akitake Mukasa
Journal:  J Neurooncol       Date:  2018-07-02       Impact factor: 4.130

4.  Expression of signal transducer and activator of transcription 3 (STAT3) in primary central nervous system diffuse large B-cell lymphoma: a retrospective analysis of 17 cases.

Authors:  Neerja Vajpayee; Juhi Hussain; Ioana Tolocica; Robert E Hutchison; Ajeet Gajra
Journal:  J Neurooncol       Date:  2010-05-06       Impact factor: 4.130

5.  Prognostic impact of MYC protein expression in central nervous system diffuse large B-cell lymphoma: comparison with MYC rearrangement and MYC mRNA expression.

Authors:  Seung-Myoung Son; Sang-Yun Ha; Hae-Yong Yoo; Dongryul Oh; Seok-Jin Kim; Won-Seog Kim; Young-Hyeh Ko
Journal:  Mod Pathol       Date:  2016-09-30       Impact factor: 7.842

Review 6.  Molecular profiling of primary central nervous system lymphomas - predictive and prognostic value?

Authors:  K Grace Ho; Christian Grommes
Journal:  Curr Opin Neurol       Date:  2019-12       Impact factor: 5.710

7.  Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma.

Authors:  Prakash Ambady; Laszlo Szidonya; Jenny Firkins; Jessica James; Kirsten Johansson; Tricia White; Caroline Jezierski; Nancy D Doolittle; Edward A Neuwelt
Journal:  Leuk Lymphoma       Date:  2018-07-22

8.  Immunohistochemical profile and prognostic significance in primary central nervous system lymphoma: Analysis of 89 cases.

Authors:  Jing Liu; Yaming Wang; Yuantao Liu; Zhe Liu; Qu Cui; Nan Ji; Shengjun Sun; Bingxu Wang; Yajie Wang; Xuefei Sun; Yuanbo Liu
Journal:  Oncol Lett       Date:  2017-09-06       Impact factor: 2.967

9.  Primary vitreoretinal lymphomas display a remarkably restricted immunoglobulin gene repertoire.

Authors:  Nabila Belhouachi; Aliki Xochelli; Myriam Boudjoghra; Claude Lesty; Nathalie Cassoux; Christine Fardeau; Thi Ha Chau Tran; Sylvain Choquet; Bishnu Sarker; Caroline Houillier; Agusti Alentorn; Phuc LeHoang; Carole Soussain; Valerie Touitou; Helene Merle-Beral; Khe Hoang-Xuan; Bahram Bodaghi; Kostas Stamatopoulos; Frederic Davi
Journal:  Blood Adv       Date:  2020-04-14

10.  Primary central nervous system lymphoma in immunocompetent individuals: a single center experience.

Authors:  Hilal Aki; Didem Uzunaslan; Caner Saygin; Sebnem Batur; Nukhet Tuzuner; Ali Kafadar; Seniz Ongoren; Buge Oz
Journal:  Int J Clin Exp Pathol       Date:  2013-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.